Retinal degeneration protein 3 (RD3) plays a crucial role in controlling guanylate cyclase activity in photoreceptor rod and cone cells, and mediates trafficking processes within photoreceptor cells. Loss of RD3 function correlates with severe forms of retinal dystrophy and the development of aggressive neuroblastoma cancer. In the present study, we analysed RD3 expression by applying a data-mining approach using public databases. In addition, we performed an RD3 transcript analysis on specimens of glioma tissues from patients. We found that RD3 is downregulated in glioblastoma compared to non-tumor tissues. Low expression of RD3 in gliomas was also associated with a poor prognosis of survival rate. Applying a multi-cohort receiver operating characteristic test, we verified significant changes in RD3 expression in glioblastomas, indicating a potential use of RD3 in glioblastoma diagnosis. The apparent influence of RD3 on cell viability or on cell cycle progression we examined by overexpressing RD3 in a cell culture system. Wild-type RD3 significantly decreased cell viability, which subsequently led to cell-cycle arrest at the G2/M phase and induced cell apoptosis. Conversely, single-point mutations in RD3 at the exposed protein surface involved in RD3 target interaction diminished the impact of RD3 wild type, thereby showing its specificity. Therefore, expression of wild type RD3 might prevent tumor progression by facilitating the death of cancer cells or arresting the cell cycle in a developing tumor. Our findings further suggest that RD3 is a potential prognostic factor in glioblastoma.